Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000492
Status:
COMPLETED
Last Update Posted:
2016-07-12
First Post:
1999-10-27
Brief Title:
Beta-Blocker Heart Attack Trial BHAT
Sponsor:
National Heart Lung and Blood Institute NHLBI
Organization:
National Heart Lung and Blood Institute NHLBI
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
1981-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine whether the regular administration of the beta-blocker drug propranolol to people who had had at least one documented myocardial infarction would result in a significant reduction of mortality from all causes over the follow-up period Eligible volunteer patients were recruited to participate in a double-blind clinical trial within 21 days after the onset of the acute event One-half of the patients were randomly assigned to a beta-blocking drug propranolol and one-half to a placebo The trial also evaluated the effect of propranolol on incidences of coronary heart disease mortality sudden cardiac death and nonfatal myocardial infarction plus coronary heart disease mortality in persons with documented previous myocardial infarction
Detailed Description:
BACKGROUND
Survivors of a documented myocardial infarction are recognized as having a high risk of dying relative to the general population Serious arrhythmias occurring with or without evidence of new infarction are a common cause of death in this population Theoretically an agent which 1 can block the sympathetic nervous activity thought to be involved in precipitating sudden death and 2 has non-neurogenic antiarrhythmic properties would be of value to people with coronary heart disease Propranolol like other beta- blocking agents has these as well as other properties and therefore might be expected to prevent or retard complications of coronary heart disease such as serious arrhythmias This would be reflected in a decrease in mortality due to coronary heart disease
A workshop on chronic antiarrhythmic therapy reviewed contemporary experimental data and clinical practice and recommended that a clinical trial be undertaken to clearly show the effects of beta-blocking drugs on mortality Subsequently such a trial was approved by the Clinical Applications and Prevention Advisory Committee by the Cardiology Advisory Committee and by the National Heart Lung and Blood Advisory Council
The study protocol was reviewed in February 1978 and recommended for approval by the policy-data monitoring board and ad hoc members The protocol was approved by the Director of NHLBI in March 1978 Recruitment started on June 19 1978 and ended in October 1980 A total of 3837 patients were randomized Units which participated in the trial included 32 clinical centers an EKG center a central laboratory a coordinating center a 1-hour ambulatory ECG center a 24-hour ambulatory EKG center and an EKG tape quality control center
DESIGN NARRATIVE
A randomized double-blind design with single experimental and control groups Patients were recruited while in the hospital for an acute myocardial infarction and were enrolled in the study before discharge Eligible patients fulfilled the study definition of an acute myocardial infarction The diagnosis was based either on electrocardiographic records showing evolving QRS segment changes or on ST segment and T wave changes together with enzyme changes and appropriate clinical history One-half of the patients were placed on therapy using a beta-blocking drug propranolol The other half received a placebo The prescribed maintenance dosage of propranolol was either l80 or 240 mgsday depending upon serum drug levels Intervention duration averaged 25 months
The study completion date listed in this record was obtained from the Completed Date entered in the Query View Report System QVR
Survivors of a documented myocardial infarction are recognized as having a high risk of dying relative to the general population Serious arrhythmias occurring with or without evidence of new infarction are a common cause of death in this population Theoretically an agent which 1 can block the sympathetic nervous activity thought to be involved in precipitating sudden death and 2 has non-neurogenic antiarrhythmic properties would be of value to people with coronary heart disease Propranolol like other beta- blocking agents has these as well as other properties and therefore might be expected to prevent or retard complications of coronary heart disease such as serious arrhythmias This would be reflected in a decrease in mortality due to coronary heart disease
A workshop on chronic antiarrhythmic therapy reviewed contemporary experimental data and clinical practice and recommended that a clinical trial be undertaken to clearly show the effects of beta-blocking drugs on mortality Subsequently such a trial was approved by the Clinical Applications and Prevention Advisory Committee by the Cardiology Advisory Committee and by the National Heart Lung and Blood Advisory Council
The study protocol was reviewed in February 1978 and recommended for approval by the policy-data monitoring board and ad hoc members The protocol was approved by the Director of NHLBI in March 1978 Recruitment started on June 19 1978 and ended in October 1980 A total of 3837 patients were randomized Units which participated in the trial included 32 clinical centers an EKG center a central laboratory a coordinating center a 1-hour ambulatory ECG center a 24-hour ambulatory EKG center and an EKG tape quality control center
DESIGN NARRATIVE
A randomized double-blind design with single experimental and control groups Patients were recruited while in the hospital for an acute myocardial infarction and were enrolled in the study before discharge Eligible patients fulfilled the study definition of an acute myocardial infarction The diagnosis was based either on electrocardiographic records showing evolving QRS segment changes or on ST segment and T wave changes together with enzyme changes and appropriate clinical history One-half of the patients were placed on therapy using a beta-blocking drug propranolol The other half received a placebo The prescribed maintenance dosage of propranolol was either l80 or 240 mgsday depending upon serum drug levels Intervention duration averaged 25 months
The study completion date listed in this record was obtained from the Completed Date entered in the Query View Report System QVR
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: